Approval of composition of matter patent in key jurisdiction underscores the Company's commitment to maximize future out-licensing value
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals" or "Conduit" or the "Company") today announced that the Japan Patent Office (JPO) has granted approval of a composition of matter patent application for the Company's lead asset, AZD1656, a Glucokinase Activator targeting a wide range of autoimmune disorders. This approval follows the recent patent grant in Australia, highlighting Conduit's continued progress in safeguarding its intellectual property portfolio for future out-licensing opportunities.
"This approval represents another significant milestone in our efforts to maximize the value of our intellectual property portfolio," said Dr. David Tapolczay, Chief Executive Officer of Conduit Pharmaceuticals. "The granting of this patent in Japan, one of the world's largest pharmaceutical markets, underscores the strength of our scientific and intellectual property strategy. We look forward to securing additional approvals in other major markets, further enhancing our global patent coverage and bolstering our out-licensing opportunities."
About Conduit Pharmaceuticals
Conduit Pharmaceuticals (Nasdaq: CDT) has developed a unique business model to bring medicines to patients. Its novel approach addresses unmet medical needs by enhancing and extending the intellectual property of its existing assets through cutting-edge solid-form technology, then commercializing these products with life science companies.
Conduit holds an exclusive license with AstraZeneca for the rights to AZD1656 and AZD5658, both Glucokinase Activators, and AZD5904, a myeloperoxidase inhibitor. Additionally, the Company has two further cocrystal assets including CDT1656, a combination of AZD1656 and a known compound, further broadening its innovative portfolio. Conduit is targeting Lupus and ANCA Vasculitis as its lead indications.
Conduit is led by a highly experienced team of pharmaceutical executives, including CEO, Dr. David Tapolczay, former Chief Executive Officer of UK-based medical research charity LifeArc, and the Chair of our Board, Dr. Freda Lewis-Hall, former Chief Medical Officer of Pfizer, Inc.
對關鍵司法管轄區事項專利構成的批准凸顯了公司對未來許可價值最大化的承諾
佛羅里達州那不勒斯和英國劍橋，2024年11月21日（GLOBE NEWSWIRE）——Conduit Pharmicals Inc.（納斯達克股票代碼：CDT）（「Conduit Pharmicals」 或 「Conduit」 或 「公司」）今天宣佈，日本專利局（JPO）已批准該公司主要資產 AZD1656 的物質組合專利申請，這是一種針對各種自身免疫性疾病的糖激酶激活劑。該批准是在澳大利亞最近獲得專利批准之後獲得的，這凸顯了Conduit在保護其知識產權組合以備將來的外包許可機會方面持續取得的進展。
Conduit Pharmicals首席執行官戴維·塔波爾扎伊博士表示：「這項批准是我們努力實現知識產權組合價值最大化的又一個重要里程碑。」「日本是世界上最大的藥品市場之一，該專利的授予凸顯了我們的科學和知識產權戰略的力量。我們期待在其他主要市場獲得更多批准，進一步擴大我們的全球專利覆蓋範圍，增加我們的外包許可機會。」
康迪特製藥公司簡介
Conduit Pharmicals（納斯達克股票代碼：CDT）開發了一種獨特的商業模式，爲患者提供藥品。其新穎方法通過尖端的固體成型技術增強和擴展其現有資產的知識產權，然後與生命科學公司將這些產品商業化，從而滿足未滿足的醫療需求。
Conduit 持有阿斯利康的獨家許可，擁有 AZD1656 和 AZD5658（均爲葡萄糖激酶激活劑）和髓過氧化物酶抑制劑 AZD5904 的版權。此外，該公司還有另外兩項共晶資產，包括 CDT1656、AZD1656 和一種已知化合物的組合，進一步擴大了其創新產品組合。Conduit 將狼瘡和 ANCA 血管炎作爲其主要適應症。
Conduit由一支經驗豐富的製藥業高管團隊領導，其中包括首席執行官、英國醫學研究慈善機構LifeArc前首席執行官戴維·塔波爾扎伊博士和我們的董事會主席、輝瑞公司前首席醫學官弗雷達·劉易斯-霍爾博士。
